Last reviewed · How we verify
EYDENZELT (AFLIBERCEPT-BOAV)
EYDENZELT (generic name: AFLIBERCEPT-BOAV) is a drug developed by CELLTRION INC. It is currently FDA-approved.
At a glance
| Generic name | AFLIBERCEPT-BOAV |
|---|---|
| Sponsor | CELLTRION INC |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Cataract
- Vitreous detachment
- Vitreous floaters
- Intraocular pressure increased
Serious adverse events
- Retinal vasculitis
- Occlusive retinal vasculitis
- Endophthalmitis
- Retinal detachment
- Retinal tear
- Hypersensitivity
- Corneal edema
- Injection site hemorrhage
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EYDENZELT CI brief — competitive landscape report
- EYDENZELT updates RSS · CI watch RSS
- CELLTRION INC portfolio CI
Frequently asked questions about EYDENZELT
What is EYDENZELT?
EYDENZELT (AFLIBERCEPT-BOAV) is a pharmaceutical drug developed by CELLTRION INC.
Who makes EYDENZELT?
EYDENZELT is developed and marketed by CELLTRION INC (see full CELLTRION INC pipeline at /company/celltrion).
What is the generic name of EYDENZELT?
AFLIBERCEPT-BOAV is the generic (nonproprietary) name of EYDENZELT.
What development phase is EYDENZELT in?
EYDENZELT is FDA-approved (marketed).
What are the side effects of EYDENZELT?
Common side effects of EYDENZELT include Conjunctival hemorrhage, Eye pain, Cataract, Vitreous detachment, Vitreous floaters, Intraocular pressure increased. Serious adverse events: Retinal vasculitis, Occlusive retinal vasculitis, Endophthalmitis, Retinal detachment.
Related
- Manufacturer: CELLTRION INC — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing